China-based Harbin Gloria Pharmaceuticals Co., Ltd (SHE: 002437) has partnered with Genolmmune Therapeutics Biotechnology Co., Ltd, a BGI Genomics subsidiary focused on tumor immune cell therapy. The collaboration aims to develop Gloria’s PD-1 monoclonal antibody zimberelimab in combination with Genolmmune’s injectable Neo-T neoantigen immunotherapy for non-small cell lung cancer (NSCLC). Financial terms were not disclosed.
Company Background
- Harbin Gloria: Founded in 2016, Gloria’s zimberelimab was approved in August 2021 for relapsed/refractory classical Hodgkin lymphoma (cHL) and is included in China’s CSCO lymphoma guidelines. The firm is conducting a Phase III trial for first-line advanced cervical cancer and has filed for second-line advanced cervical cancer.
- Genolmmune: Established in 2017, Genolmmune is China’s first tumor neoantigen drug developer. Its Neo-T platform received China’s first IND approval for a neoantigen therapy in 2020.
Collaboration Details
The partnership will focus on clinical and commercial development of the zimberelimab/Neo-T combination in NSCLC, leveraging Gloria’s PD-1 antibody and Genolmmune’s neoantigen expertise to enhance treatment efficacy.-Fineline Info & Tech
